Index
RUT
Market Cap
2.92B
Enterprise Value
2.44B
Income
-314.42M
Sales
21.38M
Book/sh
5.78
Cash/sh
3.22
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
503
IPO
Dec 08, 2017
P/E
-
Forward P/E
-
PEG
-
P/S
136.45
P/B
3.15
P/C
5.65
P/FCF
-
EV/EBITDA
-
EV/Sales
113.95
Quick Ratio
5.94
Current Ratio
6.21
Debt/Eq
0.04
LT Debt/Eq
0.03
Option/Short
Yes / Yes
EPS (ttm)
-1.74
EPS next Y
-2.25
EPS next Q
-0.61
EPS this Y
42.80%
EPS next Y
-32.53%
EPS next 5Y
17.74%
EPS past 3/5Y
-4.56% -
Sales past 3/5Y
- -
EPS Y/Y TTM
40.59%
Sales Y/Y TTM
-
EPS Q/Q
149.61%
Sales Q/Q
-
Insider Own
6.34%
Insider Trans
-0.18%
Inst Own
97.52%
Inst Trans
0.99%
ROA
-27.20%
ROE
-33.94%
ROIC
-33.06%
Gross Margin
21.42%
Oper. Margin
-2488.14%
Profit Margin
-1470.50%
SMA20
-4.99%
SMA50
-6.58%
SMA200
-13.96%
Trades
Shs Outstand
160.26M
Shs Float
150.12M
52W High
27.30 -33.33%
52W Low
15.34 18.64%
Volatility
4.56% 4.41%
ATR (14)
0.88
RSI (14)
41.22
Beta
1.06
Rel Volume
0.00
Avg Volume
1.63M
Volume
0
Perf Week
-3.65%
Perf Month
-2.57%
Perf Quarter
-26.97%
Perf Half Y
-5.70%
Perf YTD
10.24%
Perf Year
7.57%
Perf 3Y
-2.99%
Perf 5Y
-61.37%
Perf 10Y
-
Prev Close
18.20
Price
18.20
Change %
0.00%
Analysts 17 incl. previous ratings
Rating Distribution 15 Buy · 2 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Nov 13, 2026 Initiated W Wells Fargo
Overweight $35 +92.3% Jul 13, 2026 Resumed J JP Morgan
Overweight $29 +59.3% Mar 26, 2026 Reiterated H H.C. Wainwright
Buy $32 → $42 +130.8% Feb 24, 2026 Initiated W Wolfe Research
Peer Perform Jan 07, 2026 Resumed U UBS
Buy $25 +37.4% Apr 10, 2025 Upgrade C Cantor Fitzgerald
Neutral → Overweight Mar 07, 2025 Resumed M Morgan Stanley
Overweight $41 → $33 +81.3% Feb 11, 2025 Initiated D Deutsche Bank
Buy $31 +70.3% Jan 07, 2025 Initiated R Robert W. Baird
Outperform $31 +70.3% Jan 03, 2025 Initiated W William Blair
Outperform Dec 16, 2024 Upgrade S Stifel
Hold → Buy $37 +103.3% Oct 10, 2024 Resumed R Raymond James
Mkt Perform Oct 07, 2024 Downgrade C Cantor Fitzgerald
Overweight → Neutral Dec 13, 2023 Initiated C Citigroup
Buy $32 +75.8% Nov 20, 2023 Resumed J JP Morgan
Overweight $28 +53.8% Oct 24, 2023 Resumed C Cantor Fitzgerald
Overweight $85 → $35 +92.3% Sep 06, 2023 Initiated R B. Riley Securities
Buy $38 +108.8% Jan 30, 2023 Initiated S SVB Securities
Outperform $50 +174.7% Dec 05, 2022 Initiated C Cowen
Outperform Nov 02, 2022 Upgrade B BTIG Research
Neutral → Buy $38 +108.8%
Show Previous Ratings
Nov-09-26 03:26PM
Nov-03-26 07:23PM
(Earnings Whispers)
+3.13%
+7.76%
05:24PM
04:01PM
Oct-30-26 09:30AM
08:16PM
Loading…
Oct-26-26 08:16PM
(Earnings Whispers)
+3.00%
Oct-22-26 04:01PM
Aug-06-26 04:01PM
Jul-27-26 04:01PM
Jul-21-26 05:23AM
Jul-20-26 12:15PM
Jul-16-26 12:18PM
Jul-15-26 11:23AM
Jul-13-26 02:00AM
Jul-09-26 04:01PM
08:00AM
Loading…
Jun-18-26 08:00AM
06:55AM
Jun-16-26 06:18PM
May-22-26 06:46AM
May-21-26 07:03PM
06:00PM
May-07-26 04:01PM
Apr-03-26 01:30PM
Apr-01-26 08:01AM
(Investor's Business Daily)
Mar-31-26 08:49PM
Mar-25-26 02:11PM
(Investor's Business Daily)
+7.15%
11:50AM
Mar-24-26 10:00AM
Feb-27-26 09:02AM
Feb-26-26 04:01PM
08:51AM
Loading…
Feb-10-26 08:51AM
Feb-05-26 05:30PM
(MarketBeat)
-5.92%
+5.29%
02:00PM
Feb-03-26 10:00AM
Feb-02-26 08:00AM
Jan-29-26 04:00PM
Jan-20-26 10:42AM
Jan-07-26 01:01PM
Jan-06-26 08:00AM
Dec-30-25 08:00AM
Dec-29-25 09:13AM
Dec-22-25 06:11AM
Dec-10-25 04:58PM
12:14AM
Dec-09-25 04:01PM
Dec-05-25 09:56AM
05:00AM
Dec-04-25 07:00AM
Nov-10-25 08:19PM
(Insider Monkey)
+3.86%
+12.69%
Nov-07-25 01:23PM
Nov-06-25 04:01PM
04:00PM
Oct-14-25 08:23AM
07:53AM
Oct-13-25 04:01PM
Sep-10-25 11:30AM
Aug-12-25 08:18AM
Aug-11-25 04:01PM
Aug-07-25 05:15AM
Aug-05-25 09:32AM
Jul-31-25 11:58AM
Jul-30-25 08:55AM
Jul-17-25 08:15AM
Jul-16-25 09:38AM
Jul-08-25 09:59AM
Jul-07-25 08:00AM
Jun-25-25 03:27AM
Jun-05-25 11:30AM
May-07-25 01:10PM
May-06-25 04:01PM
May-05-25 09:13AM
May-02-25 01:20PM
Apr-29-25 06:42AM
Apr-03-25 09:32AM
Apr-02-25 08:00AM
Mar-28-25 09:00AM
Mar-20-25 02:16PM
08:57AM
Mar-04-25 08:00AM
Mar-03-25 12:49PM
Feb-27-25 04:01PM
Feb-06-25 11:42AM
Jan-30-25 08:00AM
Jan-17-25 11:18AM
Jan-13-25 08:00AM
Jan-08-25 08:00AM
07:25AM
Jan-07-25 04:33PM
04:08PM
(Investor's Business Daily)
02:16PM
12:48PM
10:13AM
10:13AM
09:33AM
(Investor's Business Daily)
04:41AM
Jan-06-25 04:30PM
Jan-03-25 01:08PM
Dec-17-24 06:25AM
Dec-06-24 11:31AM
Dec-05-24 08:00AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Schuth Alexander O. COFO and Secretary Nov 17 '26 Option Exercise 9.60 16,566 159,034 295,561 Nov 19 04:50 PM Chin Peter Scott Chief Medical Officer Sep 04 '26 Sale 22.29 1,654 36,868 204,538 Sep 09 04:44 PM Chin Peter Scott Officer Sep 04 '26 Proposed Sale 22.29 1,654 36,867 Sep 04 08:38 PM Thornberry Nancy Director Sep 02 '26 Sale 22.90 11,439 261,929 19,686 Sep 04 05:02 PM Schuth Alexander O. COFO and Secretary Sep 01 '26 Sale 23.44 2,768 64,882 278,995 Sep 03 04:17 PM NANCY THORNBERRY Director Sep 02 '26 Proposed Sale 23.27 11,439 266,128 Sep 02 04:31 PM ALEXANDER SCHUTH Officer Sep 01 '26 Proposed Sale 23.76 2,768 65,768 Sep 01 04:47 PM Schuth Alexander O. COFO and Secretary Aug 11 '26 Sale 25.07 2,857 71,625 281,763 Aug 13 05:01 PM Schuth Alexander O. Officer Aug 11 '26 Proposed Sale 25.07 2,857 71,624 Aug 11 05:39 PM CAROLE HO Former Affiliate Feb 05 '26 Proposed Sale 20.29 39,490 801,394 Feb 05 04:14 PM CAROLE HO Former Affiliate Feb 04 '26 Proposed Sale 21.18 150,000 3,176,970 Feb 04 04:16 PM CAROLE HO Former Affiliate Feb 03 '26 Proposed Sale 22.16 150,000 3,324,060 Feb 03 04:47 PM Watts Ryan J. President and CEO Jan 06 '26 Sale 16.50 35,198 580,767 296,833 Jan 08 04:20 PM Schuth Alexander O. COFO and Secretary Jan 06 '26 Sale 16.50 17,218 284,097 282,828 Jan 08 04:19 PM Ho Carole Consultant Jan 06 '26 Proposed Sale 16.50 17,218 284,097 Jan 06 08:28 PM Schuth Alexander O. Officer Jan 06 '26 Proposed Sale 16.50 17,218 284,097 Jan 06 08:25 PM Watts Ryan J. Director Jan 06 '26 Proposed Sale 16.50 35,198 580,767 Jan 06 08:24 PM CAROLE HO Officer Dec 04 '25 Proposed Sale 19.00 1,882 35,758 Dec 04 04:41 PM
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Co-Founder Dr. Ryan J. Watts Ph.D.
Ph.D. Dr. Alexander O. Schuth M.D.
Chief Technical and Manufacturing Officer Dr. Dana Andersen
Chief Scientific Officer Mr. Joe Lewcock Ph.D.
General Counsel Mr. Chris Walsh J.D.